SEROQUEL Research
AstraZeneca is committed to the development of innovative treatments for diseases and medical conditions
designed to improve the health of patients. Clinical research is key to obtaining FDA approval of a medicine
as being safe and effective for patients.
Clinical Development Programs
Clinical development programs for SEROQUEL were conducted in an attempt to help address unmet medical
needs in the treatment of bipolar disorder and schizophrenia. Our clinical programs broadened the scientific
base of knowledge for SEROQUEL and have led to new FDA-approved indications.
In line with our Group Corporate Responsibility Policy on transparency, we are committed to open
communication of information on AstraZeneca clinical trials. We provide information about new and ongoing
clinical trials sponsored by AstraZeneca.
For more information about AstraZeneca's research and development efforts, including results of clinical
trials with SEROQUEL, please visit our corporate Web site. US corporate Web site